Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab Discontinuation in Giant Cell Arteritis
2023-505515-21-00Phase 3Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of tocilizumab in giant cell arteritis (GCA) (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Relapse-free survival at 26 weeks. Planned start Aug 2023; status: authorised.
02
Drugs
tocilizumab
03
Conditions
giant cell arteritis (GCA)
Beyond the preview
Go deeper on 2023-505515-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505515-21-00.